NICE TA explained with appraisals and NHS funding guidance
A NICE TA is a technology appraisal of a medicine's clinical and cost effectiveness. How the process works, when the NHS must fund it and how to find one.
A NICE TA is a technology appraisal: NICE's assessment of the clinical and cost effectiveness of a medicine or other treatment, and its recommendations on NHS use (NICE). In England, a relevant health body must comply with a positive TA recommendation within the period NICE specifies. That period starts on publication and normally ends three months later (regulation 7).
NICE explains that its committees compare a new treatment with existing NHS care, weighing benefits, costs, savings and the opportunity cost of spending the money elsewhere (NICE).
A technology appraisal is not a marketing licence. A company obtains a marketing authorisation by applying to the MHRA (GOV.UK). The TA is a separate decision about whether, and for whom, the NHS should use a medicine.
Recommendations can be conditional. A TA can recommend a medicine "only if" stated conditions are met, such as population or severity restrictions, or a commercial arrangement with the company. TA676 is one example. A positive TA is not an automatic entitlement for every patient with the condition. NICE's implementation wording ties availability to its recommendations, and to the responsible clinician judging that it is the right treatment (TA1161).
How the NICE appraisal process works
NICE's explainer sets out the broad stages of a NICE health technology assessment (NICE). Not every appraisal runs through every stage in the same way. The general sequence is:
- Scope: NICE defines the question, including what the appraisal will and will not cover, with input from stakeholders.
- Evidence submission: The company submits its evidence. Other stakeholders, clinical experts and patient experts also contribute.
- Independent assessment: An independent academic centre reviews the company's evidence and prepares an external assessment report.
- Committee meeting: An independent committee weighs the evidence on clinical and cost effectiveness together with expert and patient input.
- Consultation, where needed: If the committee cannot make a positive recommendation at its first meeting, NICE issues draft recommendations for consultation.
- Final draft guidance and appeal: Consultees can appeal against the final recommendations in the final draft guidance.
- Publication: NICE publishes the recommendation. In England, the funding period starts on that date (regulation 7).
The same appraisal can produce several documents: draft recommendations for consultation, final draft guidance and the published TA (NICE). For England's funding deadline, read the published TA's implementation section, not a draft. TA1121 states its own period there.
When the NHS must fund a NICE-recommended treatment
The legal basis in England is regulation 7 of the NICE (Constitution and Functions) and Health and Social Care Information Centre (Functions) Regulations 2013. It states that "a relevant health body must comply with a technology appraisal recommendation". The usual period begins when NICE publishes the recommendation and ends three months from that date, unless NICE specifies a longer period. The 2012 Standing Rules also require arrangements so the relevant body complies with relevant NICE recommendations (regulation 34).
NICE's implementation explainer describes the usual funding period as "no later than 90 calendar days", "unless otherwise specified in the guidance" (NICE). Three months and 90 calendar days are not always the same duration. Use the deadline stated in the TA. That explainer also refers to 30 calendar days for cancer medicines. A TA can set a different period, so use the period in the guidance.
When a TA recommends a medicine as an "option", that means an option for the clinician and patient. It does not let commissioners withhold availability for use in line with the recommendation.
The published TA states the period that applies. Check its implementation section:
- Longer periods: NICE must set a longer period if it considers that appropriate, where training, infrastructure or other resources are not in place, or the technology is not yet available in England (legislation.gov.uk).
- Shorter periods: Some guidance states a faster timetable. In TA1121, cost-comparison guidance, NHS England and integrated care boards agreed to provide funding 30 days after publication.
- Phased implementation: Some TAs have explicit phased arrangements. Tirzepatide is one. NHS England's interim commissioning guidance describes access being phased in under a funding variation, rather than made available to the whole eligible population at once.
England, Wales and Scotland
Wales and Scotland do not use England's three-month rule:
| Nation | How NICE TAs apply |
|---|---|
| England | A relevant health body must comply within the period in the TA, normally three months after publication (legislation.gov.uk) |
| Wales | Health boards and the NHS Wales Joint Commissioning Committee (NWJCC) are usually expected to make a recommended medicine available for prescribing within 60 days of NICE publishing final draft guidance (AWTTC) |
| Scotland | Separate system: the Scottish Medicines Consortium provides advice to NHSScotland |
NICE guidance applies in England and Wales. The Welsh clock starts when NICE publishes final draft guidance, not the final guidance. For Northern Ireland, check the local implementation arrangements. Do not assume the England rule applies.
How to find the NICE TA for a medicine
To check which technology appraisal applies to a product:
- Search by generic name and indication. One medicine can have several TAs for different uses. Match the indication and the recommended population, not just the drug name.
- Start from NICE's list of published guidance. The technology appraisal guidance listing covers published TAs.
- Confirm the basics. Note the TA number, title and indication, publication date and status.
- Read Recommendations, then Implementation. The recommendations set the conditions and the eligible population. The implementation section sets the funding period and any variation, as in TA1121.
- Check whether it has been updated or replaced. An older saved PDF may no longer reflect current guidance. Make sure you are reading published guidance, not in-development material, a draft for consultation or final draft guidance.
For a cited summary of what a NICE technology appraisal is, how the process runs and when funding is due, see this RegAffairs AI answer on NICE TAs.